You are using an outdated browser. Please upgrade your browser to improve your experience and security.

One institution’s strategies for outpatient administration of VYXEOS for appropriate patients1,a-c

Preparation1
  • Designate a team of healthcare professionals, including registered nurses, pharmacists, APPs, and physicians
  • Thoroughly train all personnel in managing outpatient care
  • Ideally, allocate space for a dedicated patient center
Patient selection1
  • Assess patient suitability for outpatient care:
    • Ensure patients are compliant and/or have a suitable caregiver
    • Limit a patient’s commute to a treatment center to no more than 60 minutes
    • Evaluate patient’s overall health fitness (eg, ECOG performance status, risk for complications, comorbidities, etc)
    • Consider each patient’s treatment goals and preferences
Patient education1
  • Arrange calendar development and medication review
  • Educate patients and caregivers on recognizing and reporting signs and symptoms of serious complications
Patient monitoring1
  • Anticipate 2-3 monitoring visits per week, although frequency should be tailored to each patient
  • Start infusions in the morning to allow time for monitoring
  • Coordinate supportive care (eg, transfusions) to be administered following treatment/monitoring visits (same day)
  • Carefully monitor for any signs and symptoms of toxicity

Other strategies for outpatient treatment with VYXEOS

Timely access to supportive care is important in outpatient management. Supportive care may include:

blood icon

Blood and platelet transfusion support1,4,5

  • Patients may require frequent transfusions during outpatient care
vials icon

Prophylactic antimicrobial implementation1,5

  • Prophylaxis with antibacterials, antifungals, and antivirals may be recommended if a patient is considered at high risk for infection
heart in hands icon

Supportive care1

  • Supportive care such as hydration, antiemetic support, and correction of electrolyte imbalances are vital to patient care

Additional considerations for outpatient treatment

  • Inpatient access allows for unplanned admission due to urgent adverse events or if a patient requires frequent monitoring and/or transfusion support5
  • Some institutions may prefer preplanned admission to monitor patients more closely6
  • A patient who does not experience any major complications may be able to complete all treatment in an outpatient setting1

Institutions have evaluated administering VYXEOS in the outpatient setting6,7

In two small, postapproval, single-institution studies, over one-half of patients received VYXEOS induction in the outpatient setting6,7

Kubal et al6

Kubal chart

Chart legend

In a small, single-center pilot study by Kubal et al, 22 patients received a full induction course of VYXEOS6

  • Patients were evaluated each day with CBC, CMP, and uric acid and phosphorus measures
  • Planned admission occurred on Day 6 for continued care
  • 64% (n=14; median age 69) received induction in an IPOP setting, and 93% of those patients (n=13) were admitted for continued care on Day 6, as planned
  • One patient was admitted on Day 2 of induction

Deutsch et al7

Deutsch chart

Chart legend

In a small, single-center pilot study by Deutsch et al, 12 patients received a full induction course of VYXEOS7

  • Patients were monitored at least every other day until count recovery and admitted for continued care if complications occurred
  • 58% (n=7; median age 72) received induction in an IPOP setting
  • Of these 7 patients, 86% (n=6) were eventually admitted for continued care; all admissions were due to infection complications
  • One patient was admitted prior to completing the third induction dose

These two studies assessed the feasibility of adult patients receiving VYXEOS induction in the inpatient/outpatient setting6,7,d

Exclusion criteria for outpatient administration were similar across these 2 studies6,7

Kubal et al study (n=22)6 Deutsch et al study (n=12)7
Increased risk for tumor lysis including white count >50K At risk for tumor lysis syndrome
Active cardiopulmonary symptoms Signs or symptoms of active infection or cardiopulmonary disease
ECOG PS >2 ECOG PS >2
Lacked a caregiver or were unable to reside within 60 minutes of the treating facility Lacked an appropriate caregiver or transportation to the cancer center
Increased creatinine or uric acid

Treatment in an IPOP setting enables appropriate patients to receive induction in an outpatient setting, with inpatient admission scheduled as needed for continued monitoring and care or for treatment for adverse events6,7

INDICATION

VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.